Skip to main content
. 2022 Aug 10;27(10):857–863. doi: 10.1093/oncolo/oyac160

Figure 1.

Figure 1.

Payments over time, by drug class. Total industry payments to US physicians for cancer drugs in each class are shown in nominal USD. Each class is divided into those agents approved in 2014 or before (“existing”), versus 2015 or later (“new”). “Others” includes hormonal agents, antibody conjugates, and all other classes. Nominal USD.